RespireRx Pharmaceuticals Inc (fka RSPI)

[ombowstring]

moose, as I'm sure you know, Cortex's future rides on many factors. Will the FDA dosing limitations be lifted? Will Organon's trials with Org 24448 succeed? Will we get a BP partnership/licensing deal for our low and high impact programs? Will Cortex inlicense a drug that eventually comes to market and brings money into the coffers? Will our low impact(s) succeed in Phase IIb and Phase III trials? Will Cortex develop a high impact compound that proves efficacious and safe and is wildly successful in the treatment of AD, ADHD, sz, depression, etc.?

If the answers to all these questions are yes, then we could see $50-$100 a share, although the company might be bought out before that happens. If only some of the answers to these questions is yes, then we get a more modest, although significant, rise in the PPS.

It's how Cortex fares as to these questions that will determine the stock price as we move inexorably into the future.